Taysha Gene Therapies Inc

TSHA is in a Stage 4 decline with medium-term bearish tradability supported by a Lower Highs & Lower Lows pattern and recent price rejection at the 9/20/50 EMA cluster. Short-term execution favors selling now amid persistent downward momentum. Long-term uptrend remains intact above the 200 DMA but is secondary to the current decline.

• ↑100% patient response in early TASHA-102 trials achieving key milestones.
• ↑Breakthrough therapy designation from FDA streamlines regulatory approval process.
• ↓Net loss of $109M in 2025 widens operating deficits.